{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T23:50:53Z","timestamp":1783813853922,"version":"3.55.0"},"reference-count":33,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Currently, there are only a few avaailable treatment options for patients with relapsed and refractory acute myeloid leukemia (R\/R AML).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a single\u2010center, phase 1 prospective study (ChiCTR2200065634) to evaluate the efficacy and safety of chidamide, demethylating drugs (azacitidine), cytarabine, aclacinomycin, and G\u2010CSF plus venetoclax (CDCAG\u2010VEN) in patients with R\/R AML. The previous CDCAG regimen was used as a historical control to compare its efficacy and safety. Thirty and 22 patients received one course of CDCAG with or without a 14\u2010day course of venetoclax, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall response rate (ORR) was significantly higher in the CDCAG\u2010VEN group than in the CDCAG\u2010treated group (78.6% vs. 45.5%; <jats:italic>p<\/jats:italic>\u2009=\u20090.015), and the CDCAG\u2010VEN group achieved a better trend of measurable residual disease\u2010negative response (61.1% vs. 22.2%, <jats:italic>p<\/jats:italic>\u2009=\u20090.134). Compared with the CDCAG group, the CDCAG\u2010VEN group exhibited significantly better 1\u2010year overall survival (63.3% vs. 35.1%, <jats:italic>p<\/jats:italic>\u2009=\u20090.005) and progression\u2010free survival (76.7% vs. 36.0%, <jats:italic>p<\/jats:italic>\u2009=\u20090.022). The duration of response was notably better in the CDCAG\u2010VEN group than in the CDCAG group (71.2% vs. 34.3%, <jats:italic>p<\/jats:italic>\u2009=\u20090.021) and had a lower cumulative incidence of relapse (22.2% vs. 48.9%, <jats:italic>p<\/jats:italic>\u2009=\u20090.095). The neutrophil and platelet recovery times were similar between the CDCAG\u2010VEN and CDCAG groups (neutrophil: 18\u2009days vs. 19\u2009days, <jats:italic>p<\/jats:italic>\u2009=\u20090.293; platelet: 18\u2009days vs. 19\u2009days, <jats:italic>p<\/jats:italic>\u2009=\u20090.311). The frequencies of adverse events were comparable between both groups, except for a lower incidence of thrombosis in the CDCAG\u2010VEN group (0% vs. 22.7%, <jats:italic>p<\/jats:italic>\u2009=\u20090.006).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>In conclusion, venetoclax in combination with CDCAG is an effective and safe treatment regimen for R\/R AML, thereby rapidly identifying chemosensitive patients and inducing measurable residual disease\u2010negative remission in a high proportion of patients with R\/R AML.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.70734","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:52:19Z","timestamp":1741765939000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chidamide in Combination With <scp>DCAG<\/scp> With or Without Venetoclax for Relapsed\/Refractory Acute Myeloid Leukemia"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4422-0977","authenticated-orcid":false,"given":"Qingyang","family":"Liu","sequence":"first","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Senior Department of Hematology The Fifth Medical Center of Chinese PLA General Hospital  Beijing China"},{"name":"Medical School of Chinese PLA  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiawei","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Senior Department of Hematology The Fifth Medical Center of Chinese PLA General Hospital  Beijing China"},{"name":"Medical School of Chinese PLA  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lv","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Senior Department of Hematology The Fifth Medical Center of Chinese PLA General Hospital  Beijing China"},{"name":"Medical School of Chinese PLA  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linming","family":"Xu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Senior Department of Hematology The Fifth Medical Center of Chinese PLA General Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jing","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Senior Department of Hematology The Fifth Medical Center of Chinese PLA General Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Gao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Senior Department of Hematology The Fifth Medical Center of Chinese PLA General Hospital  Beijing China"},{"name":"Medical School of Chinese PLA  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Senior Department of Hematology The Fifth Medical Center of Chinese PLA General Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Dou","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Senior Department of Hematology The Fifth Medical Center of Chinese PLA General Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201003\u2010643544"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468\u20100734.2002.00058.x"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.3480"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.242"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001982"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S235430"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41587\u2010022\u201001636\u20100"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046\u2010020\u201001792\u20108"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41420\u2010022\u201001093\u20103"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071734"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010020\u201003911\u2010z"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw013"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113979"},{"key":"e_1_2_10_16_1","unstructured":"National Cancer Institute \u201cCommon Terminology Criteria for Adverse Events (CTCAE) Version 5.0 \u201d2020 https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13148\u2010020\u201000923\u20104"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010023\u201001437\u20101"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03736"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11596\u2010023\u20102805\u20107"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2006.10.006"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.CAN\u201007\u20101919"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01600"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201008\u2010868752"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.CD\u201016\u20100313"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102020\u2010134300"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(20)30060\u20107"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3788"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14082025"},{"issue":"1","key":"e_1_2_10_30_1","first-page":"72","article-title":"Fludarabine, Cytarabine, and Idarubicin With or Without Venetoclax in Patients With Relapsed\/Refractory Acute Myeloid Leukemia","volume":"109","author":"Shahswar R.","year":"2024","journal-title":"Haematologica"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14302"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26771"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(20)30525\u20108"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1182925"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.70734","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T13:29:55Z","timestamp":1741786195000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.70734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1002\/cam4.70734"],"URL":"https:\/\/doi.org\/10.1002\/cam4.70734","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-10-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70734"}}